These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 1845157)
1. Peptides containing multideterminant clusters of human immunodeficiency virus envelope induce murine and human T-cell responses in diverse histocompatibility types. Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM Trans Assoc Am Physicians; 1991; 104():69-77. PubMed ID: 1845157 [No Abstract] [Full Text] [Related]
2. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM J Clin Invest; 1991 Sep; 88(3):876-84. PubMed ID: 1715888 [TBL] [Abstract][Full Text] [Related]
3. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081 [TBL] [Abstract][Full Text] [Related]
4. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein. Bergmann C; Stohlmann SA; McMillan M Eur J Immunol; 1993 Nov; 23(11):2777-81. PubMed ID: 7693478 [TBL] [Abstract][Full Text] [Related]
5. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine. Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425 [No Abstract] [Full Text] [Related]
6. The mixotope: a combinatorial peptide library as a T cell and B cell immunogen. Estaquier J; Gras-Masse H; Boutillon C; Ameisen JC; Capron A; Tartar A; Auriault C Eur J Immunol; 1994 Nov; 24(11):2789-95. PubMed ID: 7957571 [TBL] [Abstract][Full Text] [Related]
7. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection. Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667 [TBL] [Abstract][Full Text] [Related]
8. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. Shirai M; Pendleton CD; Ahlers J; Takeshita T; Newman M; Berzofsky JA J Immunol; 1994 Jan; 152(2):549-56. PubMed ID: 8283036 [TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T cell repertoire selection. A single amino acid determines alternative class I restriction. Bergmann CC; Tong L; Cua RV; Sensintaffar JL; Stohlman SA J Immunol; 1994 Jun; 152(12):5603-12. PubMed ID: 7515908 [TBL] [Abstract][Full Text] [Related]
11. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034 [TBL] [Abstract][Full Text] [Related]
12. Current approaches to vaccination against human immunodeficiency viruses. Gluckman JC; Yagello M; Bahraoui E; Girard M Allergol Immunopathol (Madr); 1991; 19(1):11-3. PubMed ID: 1719790 [No Abstract] [Full Text] [Related]
13. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. Perales MA; Schwartz DH; Fabry JA; Lieberman J J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281 [TBL] [Abstract][Full Text] [Related]
14. N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity. Sjölander S; Bolmstedt A; Akerblom L; Horal P; Olofsson S; Morein B; Sjölander A Virology; 1996 Jan; 215(2):124-33. PubMed ID: 8560759 [TBL] [Abstract][Full Text] [Related]
15. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694 [TBL] [Abstract][Full Text] [Related]
16. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals. McElrath MJ; Corey L; Greenberg PD AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S69-72. PubMed ID: 7865336 [TBL] [Abstract][Full Text] [Related]
18. Induction of human immunodeficiency virus-specific T cell responses in rhesus monkeys by synthetic peptides from gp160. Nehete PN; Satterfield WC; Matherne CM; Arlinghaus RB; Sastry KJ AIDS Res Hum Retroviruses; 1993 Mar; 9(3):235-40. PubMed ID: 8471313 [TBL] [Abstract][Full Text] [Related]
19. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes. Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759 [TBL] [Abstract][Full Text] [Related]
20. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84. DePalma L Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387 [No Abstract] [Full Text] [Related] [Next] [New Search]